Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Docket Number (Optional)			
NOTICE OF APPEAL FROM THE EXAMINER TO		4.277.004.0004.0004.0007.00			
THE BOARD OF PATENT APPEALS AND INTERFEREN		ICES 1975.0010004/TJS/CFN/M-N			
I hereby certify that this correspondence is being facsimile transmitted	In re Applicat	l			
to the USPTO or deposited with the United States Postal Service with	UMAÑA et al.				
sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-	Application Number Filed				
1450" [37 CFR 1.8(a)]	10/633,699		August 5, 2003		
on	For See 1 in Addendum				
Signature	Lot 266 1	m Addendum	·		
	Art Unit	E	Examiner Burkhart, Michael		
Typed or printed		1633	D.		
name	<b></b>				
Applicant hereby appeals to the Board of Patent Appeals and Interference	s from the last	decision of the exan	niner.		
The fee for this Netice of Appeal is (37 CFR 41.20(b)(1))			\$ <u>\$540.00</u>		
, , , , , , , , , , , , , , , , , , , ,					
Applicant claims small entity status. See 37 CFR 1.27, Therefore, the	e fee shown ab	ove is reduced			
by half, and the resulting fee is:					
A check in the amount of the fee is enclosed.					
Payment by credit card. Form PTO-2038 is attached.					
The Director has already been authorized to charge fees in this appl	The Director has already been authorized to charge fees in this application to a Deposit Account.				
		, , , , , ,			
X The Director is hereby authorized to charge any fees which may be	The Director is hereby authorized to charge any fees which may be required, or credit any overpayment				
to Deposit Account No. 19-0036	to Deposit Account No19-0036				
X A petition for an extension of time under 37 CFR 1.136(a) (PTO/SB/	A petition for an extension of time under 37 CFR 1.136(a) (PTO/SB/22) is enclosed.				
[X] Treatment of an oxional state of a first triangle, (i.e. a see	X perition for all extension of time those 57 of N 1.150(a) (C10/05/22) is enclosed.				
WARNING: Information on this form may become public. Credi	t card informs	tion chould not			
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
I am the	geren de la		$A^{r}$ $r$ . $L$		
applicant/inventor.		<i>WW.</i>			
[T] assignee of record of the entire interest.		17	Signature		
See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed.	***************************************		y J. Sĥea, Jr.		
(Form PTO/SB/96)		Typed	or printed name		
x atterney or agent of record.		(202)	271 2600		
Registration number 41.306					
		relep	hone number		
attorney or agent acting under 37 CFR 1.34.					
Registration number if acting under 37 CFR 1.34.			Date		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.  Submit multiple forms if more than one signature is required, see below*.					
- And the second					
*Total of forms are submitted.					

This collection of information is required by 37 CFR 41.31. The information is required to obtain or retain a benefit by the public which is to file (and by the USPYO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11, 1.14 and 41.6. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## Addendum

1	Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular
1.	
	Cytotoxicity